Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2015
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Handok Inc
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 10 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register record.